Is Pimavanserin Safe to Use in Patients with Parkinson’s Disease?
This retrospective cohort study of patients with Parkinson’s disease ages 65 years or older residing in Medicare-certified long-term care facilities revealed pimavanserin use vs. nonuse is associated with an increased risk of 30-day hospitalization and higher 90-, 180-, and 365-day mortality.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.